In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on CalciMedica (CALC – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $2.37.
Gershell covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Alnylam Pharma, and Viridian Therapeutics. According to TipRanks, Gershell has an average return of -3.4% and a 33.49% success rate on recommended stocks.
Currently, the analyst consensus on CalciMedica is a Moderate Buy with an average price target of $14.00.
See the top stocks recommended by analysts >>
Based on CalciMedica’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.3 million. In comparison, last year the company had a GAAP net loss of $3.03 million
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CALC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CalciMedica (CALC) Company Description:
Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
